
Articles

The Life Sciences Sector Plan has been published - what does it mean for UK pharma?
18 Jul 2025So the Life Sciences Sector Plan has now been published on 16 July by the UK Government - just in time for everyone to enjoy some summer holiday reading. Life sciences is one of the eight chosen specialist sectors that the Government sees as key to fuelling the UK's growth in the next 10 years, as highlighted in the recent Industrial Strategy.

BioNTech £1bn investment commitment boosts UK life sciences industry
25 Jun 2025In a significant move for the UK's life sciences sector, BioNTech, renowned for its role in developing the Pfizer-BioNTech COVID-19 vaccine, has announced a £1 billion investment over the next decade.

PING Conference 2025 - Key takeaways
19 Jun 2025This paper is part of our Sustainability Insights series following the 2025 PING Conference on Sustainability - What must Pharma do now? - bringing you expert perspectives and practical takeaways from key discussions shaping the future of businesses looking to address the threats and opportunities of sustainability in the life sciences sector. Thanks to Hertfordshire Futures for their great support of PING yet again.

The Association of the British Pharmaceutical Industry (ABPI) has issued a policy proposal aimed at supporting the delivery of the NHS 10-Year Plan.
13 May 2025The plan is built around three core shifts in care: from hospital to community, from analogue to digital, and from treatment to prevention. These shifts reference the government’s ambition to deliver economic growth through improved health outcomes.

NICE introduces promising improvements to the routing criteria for highly specialised technologies designed to treat rare diseases
13 May 2025The newly approved routing criteria is hoped to clearly define the circumstances for when highly specialised technologies (HSTs) will be routed to the HST programme which is designed to evaluate technologies for ultra-rare debilitating conditions.

ABPI and UK Government bring forward VPAG pricing review
01 May 2025The UK Government and the Association of the British Pharmaceutical Industry (ABPI) have agreed to accelerate the planned review of the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG).







